Trademarkia Logo

Canada

C$
Trademark Search in Canada
REMSEQ

View On IC.GC.CA

REMSEQ
CANCELLED

Last Applicant/ Owned by

Remix Therapeutics, Inc.

400 Technology Square Cambridge MA 02139

US

Serial Number

2045350 filed on 12th May 2020

Registration Number

TMA1235519 registered on 31st May 2024

Registration expiry Date

12th May 2030

Correspondent Address

MOFFAT & CO.

P.O. Box 2088, Station DOttawa

ONTARIO

CA

K1P5W3

REMSEQ

Trademark usage description

pharmaceutical and therapeutic preparations for the treatment of cancer; pharmaceutical and therapeutic preparations for the treatment of immune syste Read More

Classification Information

Class [005]
Pharmaceutical and therapeutic preparations for the treatment of cancer; pharmaceutical and therapeutic preparations for the treatment of immune system related diseases and disorders, namely, arthritis, Chagas disease, chronic obstructive pulmonary disease (COPD), dermatomyositis, diabetes mellitus type 1, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, Hidradenitis suppurativa, Kawasaki disease, ankylosing spondylitis, IgA nephropathy (aka Berger's disease), idiopathic thrombocytopenic purpura, inflammatory bowel disease, Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischemic colitis, diversion colitis, Behcet's syndrome, infective colitis, indeterminate colitis, interstitial cystitis, lupus, mixed connective tissue disease (MCTD), morphea, multiple sclerosis, myasthenia gravis, narcolepsy, neuromyotonia (NMT), pemphigus vulgaris, pernicious anemia, psoriasis, psoriatic arthritis, polymyositis, primary biliary cirrhosis (PBC), relapsing polychondritis (RP), scleroderma, Sjögren's syndrome, Stiff person syndrome (SPS), vasculitis, vitiligo, GATA-binding factor 2 (aka GATA2) mutation-derived (such as GATA2 deficiency, GATA2 haploinsufficiency, Emberger syndrome, monocytopenia and mycobacterium avium complex/dendritic cell, monocyte, B and NK lymphocyte deficiency, familial myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia), neutropenia, aplastic anemia, and Wegener's granulomatosis, chronic mucocutaneous candidiasis (CMCC); pharmaceutical and therapeutic preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical and therapeutic preparations for the treatment of genetic diseases and disorders; pharmaceutical and therapeutic preparations for the treatment of neurological diseases and disorders, namely, tri/penta/hexa/dodeca-nucleotide repeat expansion-derived, Alzheimer's disease, Huntington's chorea, prion diseases (namely, Creutzfeld-Jacob disease (CJD), Variant Creutzfeldt-Jakob disease (vCJD), Fatal Familial insomnia (FFI), Kuru, bovine spongiform encephalopathy (BSE), scrapie, Chronic wasting disease (CWD), Feline spongiform encephalopathy (FSE), Transmissible mink encephalopathy (TME), Ungulate spongiform encephalopathy), mental retardation (MR, now called intellectual disability (ID)), Lewy Body disease, diffuse Lewy body disease (DLBD), dementia, progressive supranuclear palsy (PSP), progressive bulbar palsy (PBP), pseudobulbar palsy, spinal and bulbar muscular atrophy (SBMA), primary lateral sclerosis (PLS), Pick's disease, primary progressive aphasia, corticobasal dementia, Parkinson's disease, Down's syndrome, multiple system atrophy (MSA), spinal muscular atrophy (SMA), progressive spinobulbar muscular atrophy, post-polio syndrome (PPS), spinocerebellar ataxia (SCA), pantothenate kinaseassociated neurodegeneration (PKAN), spinal degenerative diseases, motor neuron degenerative diseases, upper motor neuron disease, lower motor neuron disease, Hallervorden-Spatz syndrome, cerebral infarction, cerebral trauma, chronic traumatic encephalopathy (CTE), transient ischemic attack (TIA), Lytico-bodig (amyotrophic lateral sclerosis-parkinsonism dementia), Guam-Parkinsonism dementia, hippocampal sclerosis (HS), corticobasal degeneration, Alexander disease, Alpers' disease, Krabbe disease (KD), neuroborreliosis, neurosyphilis, Sandhoff disease, Tay-Sachs disease, Schilder's disease, Batten disease, Cockayne syndrome (CS), Kearns-Sayre syndrome (KSS), Gerstmann-Straussler-Scheinker syndrome and other transmissible spongiform encephalopathies, hereditary spastic paraparesis (HSP), Leigh's syndrome, demyelinating disease, neuronal ceroid lipofuscinoses (NCL), epilepsy, tremors, depression, mania, anxiety and anxiety disorders, sleep disorders, acute brain injuries, autism, Machado-Joseph disease (MJD).

Classification kind code

11

Class [042]
Pharmaceutical, medical, and biopharmaceutical research and development.

Classification kind code

11

Mark Details

Serial Number

2045350

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 22
on 8th Dec 2021		Search Recorded
Submitted for opposition 20
on 8th Dec 2021		Examiner's First Report
Submitted for opposition 223
on 8th Dec 2021		Total Provisional Refusal
Submitted for opposition 256
on 14th Jun 2021		Notification of Possible Opposition Sent
Submitted for opposition 48
on 5th Feb 2021		Agent Changed
Submitted for opposition 257
on 13th Aug 2020		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 12th Aug 2020		Created
Submitted for opposition 31
on 12th Aug 2020		Formalized
Submitted for opposition 30
on 12th May 2020		Filed
Submitted for opposition 228
on 12th May 2020		International Registration